Medicsight files 510(k) application with US FDA for ColonCAD
This article was originally published in Clinica
Computer-aided detection (CAD) company Medicsight (London, UK) has submitted a 510(k) application to the US FDA for its ColonCAD software. The technology helps to identify early-stage colon cancer, using a CAD algorithm to analyse CT scans and automatically highlight suspicious areas. These include areas too small for the radiologist to see, or hidden behind folds in the colon. ColonCAD is already approved in Europe, Canada, Australia, China and Brazil. CT colonography, also known as "virtual colonscopy", was added to the American Cancer Society guidelines for colon cancer screening this year. As it is noninvasive, it could be used in those who do not wish to undergo colonoscopy.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.